Antimicrobial resistance of Acinetobacter spp. in Europe

被引:240
作者
Van Looveren, M
Goossens, H
机构
[1] Univ Antwerp Hosp, UA, Dept Med Microbiol, Antwerp, Belgium
[2] Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RA Leiden, Netherlands
[3] Leiden Univ, Med Ctr, ESCMID Study Grp Anitmicrobial Resistance Surveil, NL-2300 RA Leiden, Netherlands
关键词
Acinetobacter; antimicrobial resistance; carbapenems; Europe; review; surveillance;
D O I
10.1111/j.1469-0691.2004.00942.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive revision in the mid-1980s, and at least 32 named and unnamed species have now been described. Of these, Acinetobacter baumannii and the closely related unnamed genomic species 3 and 13 sensu Tjernberg and Ursing (13TU) are the most relevant clinically. Multiresistant strains of these species causing bacteraemia, pneumonia, meningitis, urinary tract infections and surgical wound infections have been isolated from hospitalised patients worldwide. This review provides an overview of the antimicrobial susceptibilities of Acinetobacter spp. in Europe, as well as the main mechanisms of antimicrobial resistance, and summarises the remaining treatment options for multiresistant Acinetobacter infections.
引用
收藏
页码:684 / 704
页数:21
相关论文
共 146 条
  • [1] Worldwide emergence of carbapenem-resistant Acinetobacter spp.
    Afzal-Shah, M
    Livermore, DM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (05) : 576 - 577
  • [2] Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii
    Afzal-Shah, M
    Woodford, N
    Livermore, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) : 583 - 588
  • [3] Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in Turkey
    Aksaray, S
    Dokuzoguz, B
    Güvener, E
    Yücesoy, M
    Yulug, N
    Kocagöz, S
    Ünal, S
    Çetin, S
    Calangu, S
    Günaydin, M
    Leblebicioglu, H
    Esen, S
    Bayar, B
    Willke, A
    Findik, D
    Tuncer, I
    Baysal, B
    Günseren, F
    Mamikoglu, L
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (05) : 695 - 699
  • [4] SKIN AS THE SOURCE OF ACINETOBACTER AND MORAXELLA SPECIES OCCURRING IN BLOOD CULTURES
    ALKHOJA, MS
    DARRELL, JH
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1979, 32 (05) : 497 - 499
  • [5] AMYES SGB, 1996, ACINETOBACTER MICROB, P185
  • [6] Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features
    BergogneBerezin, E
    Towner, KJ
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) : 148 - +
  • [7] Distribution of Acinetobacter species on skin of healthy humans
    Berlau J.
    Aucken H.
    Malnick H.
    Pitt T.
    [J]. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18 (3) : 179 - 183
  • [8] Outbreak of septicaemia in neonates caused by Acinetobacter junii investigated by amplified ribosomal DNA restriction analysis (ARDRA) and four typing methods
    Bernards, AT
    deBeaufort, AJ
    Dijkshoorn, L
    vanBoven, CPA
    [J]. JOURNAL OF HOSPITAL INFECTION, 1997, 35 (02) : 129 - 140
  • [9] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain
    Betriu, C
    Rodríguez-Avial, I
    Sánchez, BA
    Gómez, M
    Alvarez, J
    Picazo, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 892 - 895
  • [10] Blondeau JM, 1999, CLIN THER, V21, P3